Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mucinous cystic neoplasms of the liver and pancreas: relationship between KRAS driver mutations and disease progression.

Histopathology - 1 Oct 2017

Fujikura Kohei, Akita Masayuki, Abe-Suzuki Shiho, Itoh Tomoo, Zen Yoh

Abstract excerpt

AIMS: To compare the oncogenic mutation status among mucinous cystic neoplasms (MCNs) of different histological grades and between liver and pancreatic MCNs. METHODS AND RESULTS: KRAS, GNAS, RNF43 and PIK3CA were sequenced in 25 surgical cases of hepatopancreatic MCN. Molecular features were correlated with clinicopathological and immunohistochemical findings. KRAS mutations were identified in five cases (20%),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aged
Share to Disease Progression

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Liver Neoplasms

Share to Mutation

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to Young Adult

Source

Identifiers

PMID: 28570009
DOI: 10.1111/his.13271

Genes

KRAS
GNAS
RNF43
MUC2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mucinous cystic neoplasms of the liver and pancreas: relationship between KRAS driver mutations and disease progression.PMID 28570009Read ↗

Mucinous Cystic Neoplasms Lined by Abundant Mucinous Epithelium Frequently Involve KRAS Mutations and Malignant Progression.Semantic proximity Read ↗

Genomic Characterization of Low- and High-Grade Pancreatic Mucinous Cystic Neoplasms Reveals Recurrent KRAS Alterations in "High-Risk" Lesions.Semantic proximity Read ↗

Intraductal papillary mucinous neoplasms of the pancreas: Clinical association with KRAS.Semantic proximity Read ↗

Activation of the RAS pathway through uncommon BRAF mutations in mucinous pancreatic cysts without KRAS mutation.Semantic proximity Read ↗

Preoperative GNAS and KRAS testing in the diagnosis of pancreatic mucinous cysts.Semantic proximity Read ↗

Integration of KRAS testing in the diagnosis of pancreatic cystic lesions: a clinical experience of 618 pancreatic cysts.Semantic proximity Read ↗

GNAS and KRAS mutations are common in intraductal papillary neoplasms of the bile duct.Semantic proximity Read ↗

Next-generation sequencing adds value to the preoperative diagnosis of pancreatic cysts.Semantic proximity Read ↗

Molecular analysis of EUS-acquired pancreatic cyst fluid for KRAS and GNAS mutations for diagnosis of intraductal papillary mucinous neoplasia and mucinous cystic lesions: a systematic review and meta-analysis.Semantic proximity Read ↗

Activating mutations of GNAS and KRAS in cystic fluid can help detect intraductal papillary mucinous neoplasms of the pancreas.Semantic proximity Read ↗

Diagnostic accuracy and risk stratification of pancreatic cyst fluids diagnosed as mucinous neoplasms without mucinous epithelium.Semantic proximity Read ↗

Clinical Impact of KRAS and GNAS Analysis Added to CEA and Cytology in Pancreatic Cystic Fluid Obtained by EUS-FNA.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.